{"entity":{"id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","aka":["Precem-TcT"],"tldr":"Precemtabart tocentecan is an experimental antibody-drug conjugate from EMD Serono Research & Development Institute in phase 3 trials for colorectal cancer, aimed at CEACAM5.","summary":"Precemtabart tocentecan is an antibody-drug conjugate developed by EMD Serono Research & Development Institute. Its target is CEACAM5 (the sponsor names CEACAM5). The sponsor states: An antibody-drug conjugate against CEACAM5 carrying an exatecan (topoisomerase inhibitor) payload, given intravenously once every three weeks. ClinicalTrials.gov describes the intervention as: Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07549412 (A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)), in colorectal cancer. The largest, NCT07549412, plans to enrol 1020 participants with primary completion expected 2029-10-16. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Precemtabart tocentecan","url":"https://clinicaltrials.gov/search?intr=Precemtabart%20tocentecan"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["ceacam5"],"drugs":[],"companies":["merck-kgaa"],"institutions":[],"pathways":[],"terms":[],"trials":["proceade-crc-03","nct06710132"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"An antibody-drug conjugate against CEACAM5 carrying an exatecan (topoisomerase inhibitor) payload, given intravenously once every three weeks.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/precemtabart-tocentecan/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/"}],"company":[{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"}],"trial":[{"id":"proceade-crc-03","kind":"trial","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","route":"/trials/proceade-crc-03/"},{"id":"nct06710132","kind":"trial","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","route":"/trials/nct06710132/"}]}}